Statins have outstanding high potency for diabetes and cataract risk
Two high-intensity statin regimens showed similar clinical efficacy when directly compared in secondary prevention, but one regimen was associated with a higher risk of diabetes and cataracts in results from the LODESTAR trial. Whether they were randomized to rosuvastatin (Crestor) or atorvastatin (Lipitor), those with existing coronary artery disease (CAD) had no statistically significant difference … Read more
